Agenixs

Agenix is a publicly traded Australian biotechnology company focused on the development of advanced medical diagnostics and small molecule therapeutics. The company's lead diagnostic candidate, ThromboView, is a radiolabeled monoclonal antibody fragment designed to detect live blood clots in patients with suspected pulmonary embolism or deep vein thrombosis. In addition to its diagnostic portfolio, Agenix has expanded into the anti-infective space with AGX-1009, a prodrug of tenofovir aimed at treating chronic Hepatitis B. The company operates primarily through its subsidiaries and has established a significant presence in the Asian market, particularly in China, to facilitate clinical development and commercialization.